/
BNR
$8.08-$0.19 (-2.30%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$87.2M
11M shares
52-week range
$3.11 – $41.72
13% from low
Exchange
NASDAQ
ADRC
Borrow rate
3.40%
Moderate
Price (6 mo)
Loading chart…
Change$-265.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $208.9M | $381.7M | $429.9M | $507.9M | $563.2M | $537.4M | $515.8M | $539.6M |
| Cost of revenue | $73.8M | $108.3M | $116.0M | $143.7M | $183.2M | $174.2M | $153.4M | $136.7M |
| Gross profit | $135.1M | $273.3M | $313.9M | $364.1M | $380.0M | $363.2M | $362.4M | $402.9M |
| Gross margin | 64.7% | 71.6% | 73.0% | 71.7% | 67.5% | 67.6% | 70.3% | 74.7% |
| R&D | $105.3M | $156.9M | $263.9M | $367.9M | $421.9M | $347.0M | $232.3M | $166.5M |
| Operating income | −$161.4M | −$169.1M | −$412.4M | −$797.1M | −$980.4M | −$669.3M | −$357.6M | −$54.8M |
| EBITDA | −$135.9M | −$128.8M | −$373.3M | −$746.5M | −$845.2M | −$517.9M | −$270.2M | −$32.0M |
| Net income | −$177.5M | −$168.3M | −$407.2M | −$796.7M | −$971.2M | −$653.7M | −$346.6M | −$55.3M |
| Net margin | -85.0% | -44.1% | -94.7% | -156.9% | -172.4% | -121.6% | -67.2% | -10.3% |
| EPS (diluted) | -103.82 | -142.30 | -68.76 | -76.45 | -93.47 | -63.84 | -33.67 | -49.60 |
Annual figures · source: Financial Modeling Prep
Peer comparison
Burning Rock Biotech Limited American Depositary Shares
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
www.brbiotech.com- Employees
- 667
- IPO / List date
- Jun 12, 2020
Held by traders on TradeandTell
No one on the platform currently holds BNR.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 35,407 | $571.1K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-05-15 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded BNR yet.
